Download Jon`s bare standard

Simon Brewster: PUBLICATIONS IN JOURNALS
1.
THE DEVELOPMENT AND DIFFERENTIATION OF HUMAN SEMINAL VESICLES
SF Brewster
Journal of Anatomy 1985; 143: 45 - 55.
2.
THE DEVELOPMENT OF THE LIGAMENT OF THE HEAD OF THE FEMUR
SF Brewster
Clinical Anatomy 1990; 4: 245 - 255.
3.
A MALE PSEUDOHERMAPHRODITE WITH NOONAN’S SYNDROME
SF Brewster, RM Kennedy, PJB Smith
British Journal of Urology 1992; 67: 96 - 97.
4.
THE VARICOSE VEIN WAITING LIST - RESULTS OF A VALIDATION EXERCISE
SF Brewster, S Nicholson, JR Farndon
Annals of the Royal College of Surgeons 1991; 73: 223 - 226.
5.
CAN KNEE REPLACEMENTS BE ASSESSED BY POST?
SF Brewster, JH Newman
Health Trends 1991; 23: 113 - 114.
6.
INTRA-VESICAL FOREIGN BODIES - A FIVE-YEAR REVIEW
SD Eckford, RA Persad, SF Brewster, JC Gingell
British Journal of Urology 1992; 69: 41 - 45.
7.
TUMOUR SUPPRESSOR GENES IN URINARY TRACT ONCOLOGY - A REVIEW
SF Brewster, JC Gingell, KW Brown
British Journal of Urology 1992; 70: 585 - 590.
8.
TRANSRECTAL BIOPSY - RESULTS OF ANTIMICROBIAL PROPHYLAXIS QUESTIONNAIRE
SF Brewster
British Journal of Urology 1992; 70: 596.
9.
ADVANCED PROSTATE CANCER - WHAT’S NEW IN HORMONAL MANIPULATION?
SF Brewster and DA Gillatt
British Journal of Hospital Medicine 1993; 49 : 710-715.
10.
A FATAL ANAEROBIC SEPSIS FOLLOWING TRANSRECTAL BIOPSY OF A RARE PROSTATIC TUMOUR
SF Brewster, N Rooney, J Kabala, RCL Feneley
British Journal of Urology 1993; 77 : 977 - 978.
11.
GENE THERAPY FOR CANCER: WHAT’S IT ALL ABOUT?
SF Brewster
Hospital Update 1994 ; 20 : 140 - 150.
12.
SOMATIC ALLELIC LOSSES AT TUMOUR SUPPRESSOR GENES DCC, p53, nm23-HI AND APC LOCI IN HUMAN
PROSTATIC CARCINOMA
SF Brewster, S Browne, KW Brown
Journal of Urology 1994 ; 151: 1073 - 1077.
13.
PELVIC APPENDICITIS IN YOUNG MALES MASQUERADING AS CYSTITIS
SF Brewster, A Lovering, J McLoughlin
Journal of the Royal College of Surgeons of Edinburgh 1994; 39: 119 - 120.
14.
GENE THERAPY IN UROLOGICAL ONCOLOGY : PRINCIPLES, STRATEGIES AND POTENTIAL
SF Brewster and JW Simons
European Urology, 1994; 25: 177 - 182.
15.
THE ACUTE SURGICAL ADMISSION: IS MORTALITY PREDICTABLE IN THE ELDERLY?
RH Kennedy, AM Al-Mufti, SF Brewster, EN Sherry, TR Magee, TT
Irvin. Annals of the Royal College of Surgeons 1994; 76: 342 - 345.
16.
SCREENING FOR PROSTATE CANCER IN GENERAL PRACTICE - RESULTS OF A 3-YEAR FOLLOW-UP
SF Brewster, T Kemple, A MacIver, P Astley and JC Gingell
British Journal of Urology 1994; 74: 556 - 558.
17.
LOSS OF HETEROZYGOSITY ON CHROMOSOME 18q IS ASSOCIATED WITH MUSCLE-INVASIVE TRANSITIONAL
CELL CARCINOMA OF THE BLADDER
SF Brewster, JC Gingell and KW Brown
British Journal of Cancer 1994; 70: 697-700.
18.
THE ROLE OF CANCER GENES IN THE DEVELOPMENT OF PROSTATE CANCER
SF Brewster
Endocrine-related Cancer 1994; 3: 27 - 39.
19.
THE PROSPECTS OF GENE THERAPY FOR UROLOGICAL MALIGNANCY
SF Brewster
Current Medical Literature: Urology 1995; 1: 31 - 36.
20.
ANTIMICROBIAL PROPHYLAXIS FOR TRANSRECTAL BIOPSY OF THE PROSTATE: A PROSPECTIVE RANDOMISED
TRIAL.
SF Brewster, AG MacGowan & JC Gingell
British Journal of Urology 1995; 76: 351-354.
21.
Reply to letter commenting on “ANTIMICROBIAL PROPHYLAXIS FOR TRANSRECTAL BIOPSY OF THE PROSTATE: A
PROSPECTIVE RANDOMISED TRIAL”
SF Brewster, AG MacGowan & JC Gingell.
British Journal of Urology 1995; 76: 351-354.
British Journal of Urology 1996; 77: 618-619.
22.
THE TUMOUR SUPPRESSOR GENE nm23-H1 IN BLADDER CANCER
F Brewster & JC Gingell
British Journal of Urology 1996; 78: 321-322(letter)..
23.
PROBLEMS IN DIAGNOSIS AND MANAGEMENT OF GOITRE IN CHILDHOOD AND ADOLESCENCE.
AJ Webb, SF Brewster & D Newington
British Jourmal of Surgery 1996; 83: 1586-1590.
24.
ANTIMICROBIAL PROPHYLAXIS FOR PROSTATIC BIOPSY
SF Brewster
Current Opinion in Urology 1997; 7: 57-60.
25.
INACTIVATION OF THE RETINOBLASTOMA SUSCEPTIBILITY GENE (RB1) IN EYE AND BLADDER TUMOURS FROM
THE SAME PATIENT
Simon F Brewster, Margaret Knowles, David Poller and J Gingell
British Journal of Urology, 1998; 81: 494-495.
26.
P53, BCL-2, CD44 AND E-CADHERIN AS PREOPERATIVE PREDICTORS OF TREATMENT FAILURE AFTER RADICAL
PROSTATECTOMY.
Simon F Brewster, Jon Oxley, Clive Abbott and David A Gillatt
Jounal of Urology, 1999; 161: 1238-1243.
27.
UROLOGY AND THE INTERNET: AN EVALUATION OF INTERNET USE BY UROLOGY PATIENTS AND OF
INFORMATION AVAILABLE ON UROLOGICAL TOPICS.
G.O. Hellawell, KJ Turner, KJ Le Monnier and SF Brewster
British Journal of Urology, 2000; 86: 191-194.
28.
UP-REGULATION AND ALTERED DISTRIBUTION OF IGF-1 RECEPTOR IN HUMAN PROSTATE CANCER.
G.O. Hellawell, D.R. Davies, H. Turley, SF Brewster and V.M. Macaulay
British Journal of Urology, 2000; 86: 360-393.
29.
DIGITAL RECTAL EXAMINATION BY MEDICAL STUDENTS AND HOUSE OFFICERS. TAUGHT, NOT DONE.
K.J. Turner and S.F. Brewster
Prostate Cancer and Prostatic Diseases, 2000; 3, 128-129.
30.
RANDOMISED TRIALS IN EARLY PROSTATE CANCER II: HORMONE THERAPY AND RADIOTHERAPY FOR
LOCALLY-ADVANCED DISEASE: A QUESTION STILL UNANSWERED.
MJ Mason, S Brewster, LE Moffat, P Kirkbride, RA Cowan, P Malone, M Sydes, & MK Parmer
Clinical Oncology, 2000; 12: 215-216.
31.
THE ATTITUDES AND USES OF ALTERNATIVE THERAPIES BY UK PROSTATE CANCER PATIENTS – ISN’T IT TIME
WE WERE IN THE KNOW?.
P Cheetham, K LeMonnier & SF Brewster
Prostate Cancer and Prostatic Diseases, 2001; 4, 235-241.
32.
p53 and bcl-2 IMMUNOHISTOCHEMISTRY IN PREOPERATIVE BIOPSIES AS PREDICTORS OF BIOCHEMICAL
RECURRENCE AFTER RADICAL PROSTATECTOMY
JD Oxley, MH Winkler, K Parry, SF Brewster, C Abbott & DA Gillatt
BJU International, 2002; 89, 27-32.
33.
GROWTH FACTORS AND THEIR RECEPTORS IN PROSTATE CANCER
GO Hellawell &SF Brewster
BJU International, 2002; 89, 230-240.
34.
PROSTATE CANCER
SF Brewster
J Ass Ch Phys Wom Health 2002; 90, 17-18.
35.
CAN SAW PALMETTO HELP IN PROSTATE CANCER?
SF Brewster
Pulse 2002; 62, 60.
36.
SCREENING FOR PROSTATE CANCER IN THE UK
J Ord & SF Brewster
BMJ Rapid Response 18/04/2002 http://www.bmj.com/cgi/eletters/323/7316/763
37.
EXPRESSION OF THE TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR IS UP-REGULATED IN PRIMARY
PROSTATE CANCER AND COMMONLY PERSISTS IN METASTATIC DISEASE
GO Hellawell, GH Turner, DR Davies, R Poulsom , SF Brewster & VM Macaulay
Cancer Research 2002; 62, 2942-2950.
38.
BMJ USA : Letter
S Brewster, M Feneley & R Kirby
BMJ Rapid Response 4/10/2002 http://www.bmj.com/cgigi/content/full/bmj%3B327/7418/E177
39.
OPPORTUNITIES AND OUTCOMES IN EARLY PROSTATE CANCER: A COMMENTARY ON POLICY, PATIENT
PERSPECTIVES, TRIALS AND STRATEGIES
M.R. Feneley & S. Brewster
BJU International 2003; 91, 177-178.
40.
CHEMOSENSITISATION OF HUMAN PROSTATE CANCER USING ANTISENSE AGENTS TARGETING THE TYPE-1
INSULIN-LIKE GROWTH FACTOR RECEPTOR
GO Hellawell, D.J.P. Ferguson, SF Brewster & VM Macaulay
BJU International 2003; 91, 271-277.
41.
THE USE OF ASPIRIN WITH PC-SPES MAY NOT PREVENT PULMONARY EMBOLISM
SM Biers & SF Brewster
BJU International 2003; 91, 428.
42.
Editorial Comment on BIOCHEMICAL DISEASE-FREE SURVIVAL IN PATIENTS WITH A HIGH PSA AND CLINICALLYLOCALIZED PROSTATE CANCER AFTER RADICAL PROSTATECTOMY by Brandli DW et al. BJU International 2003; 92,
19-22.
SF Brewster
BJU International 2003; 92, 22-23.
43.
THE TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR IS OVER-EXPRESSED IN BLADDER CANCER, AND
TARGETING BY RNA INTERFERENCE REDUCES IN VITRO SURVIVAL.
Rochester MA, Patel N, Hellawell GO, Brewster SF & Macaulay VM.
J Urol 2004: 171, S195.
44.
GENETICS FOR UROLOGISTS.
Rochester MA, & Brewster SF.
BJUI EBU Update 2004: 94, 232.
45.
A DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIAL OF TOPICAL GLYCERYLTRINITRATE FOR TRANSRECTAL
ULTRASOUND GUIDED PROSTATE BIOPSY.
Rochester MA, Le Monnier K, Brewster SF.
J Urol. 2005: 173(2):418-20.
46.
SILENCING OF THE IGF1R GENE ENHANCES SENSITIVITY TO DNA-DAMAGING AGENTS IN BOTH PTEN WILDTYPE AND MUTANT HUMAN PROSTATE CANCER.
Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM.
Cancer Gene Ther. 2005: 12(1): 90-100.
47.
LONG-TERM OUTCOMES AND MORBIDITY AFTER I125 BRACHYTHERAPY FOR LOCALISED PROSTATE
CANCER: AN EARLY UK SERIES.
Hellawell GO, Le Monnier K,Davies D, Fellows GJ, Whipp E and Brewster SF.
Clinical Oncology 2005: 17, 68.
48.
Wnt SIGNALLING and PROSTATE CANCER.
Yardy GW & Brewster SF.
Prostate Cancer & Prostatic Diseases 2005: 8, 119-126.
49.
THE WNT SIGNALING PATHWAY IS A POTENTIAL THERAPEUTIC TARGET IN PROSTATE CANCER.
Yardy GW & Brewster SF.
BJU International 2006; 98, 719-21.
50.
ARE 2 REPEAT PROSTATE BIOPSIES SUFFICIENT TO DETERMINE THE OUTCOME OF HIGH-GRADE PIN AND ASAP
ON INITIAL PROSTATE BIOPSY?
W.C. Tsang, I.S.D Roberts and S. Brewster.
Eur Urol 2007: 6, 123.
51.
HIGH-INTENSITY FOCUSSED ULTRASOUND FOR LOCALISED PROSTATE CANCER: INTRA-OPERATIVE
DETERMINANTS OF BIOPSY-PROVEN FAILURE USING THE SONABLATE 500 SYSTEM.
Calleary J, Leslie T, Illing R, Kennedy J, Brewster S, Allen C, Emberton M.
Eur Urol 2007: 6, 123.
52.
PATIENTS’ PERCEPTIONS OF TRANSRECTAL PROSTATE BIOPSY: A QUALITATIVE STUDY.
Chapple AB, Ziebland S, Brewster S & Mcpherson A.
Eur J Cancer 2007: 16, 215-221.
53.
A RANDOMISED CONTROLLED TRIAL OF TOPICAL GTN BEFORE TRUS-GUIDED BIOPSY (letter).
Brewster S & Rochester M.
BJU International 2007: 100, 1412-1413.
54.
SINGLE FOCUS PROSTATE CANCER ON TRUS BIOPSY – DOES SIZE MATTER?
Tsang WC, Kaur J, Robert I and Brewster S.
Eur Urol 2008: 7, 274.
55.
NICE GUIDANCE ON PROSTATE CANCER AND THE ROLE OF ACTIVE SURVEILLANCE FOR LOW-RISK, LOCALISED
DISEASE.
Marsh HP & Brewster SF.
BMJ Rapid Response March 2008. http://www.bmj.com/cgi/eletters/336/7644/610#192523
56.
LOW-RISK LOCALISED PROSTATE CANCER: ARE WE READY TO RECOMMEND ACTIVE SURVEILLANCE AS THE
PREFERRED OPTION?
Brewster SF.
BJUI 2008: 102, 923-926.
57.
MUTATIONS IN THE AXIN1 GENE IN ADVANCED PROSTATE CANCER
Yardy GW, Bicknel DC, Wilding JL, Bartlett S, Lui Y, Winney B, Turner G, Brewster SF & Bodmer WF.
Eur Urol 2009: 56; 486-494.
58.
HIGH-INTENSITY FOCUSED ULTRASOUND FOR LOCALISED PROSTATE CANCER: INITIAL EXPERIENCE WITH A 2YEAR FOLLOW-UP.
Leslie T & Brewster S.
BJUI 2010: 105, 726-727.
59.
CHALLENGING THE EAU 2009 GUIDELINES ON TESTIS CANCER: THE RISK-ADAPTED MANAGEMENT OF STAGE I
NONSEMINOMATOUS GERM CELL TUMOURS: SURVEILLANCE YIELDS EQUAL RESULTS WITH LESS TOXICITY.
Brewster SF.
Eur Urol Supps. 2010: 9; 459-461.
60.
FOCAL THERAPY FOR PROSTATE CANCER; POSSIBILITIES AND LIMITATIONS.
Eggener S, Salomon G, Scardino, PT, De la Rosette J, Polascik TJ, Brewster S.
Eur Urol 2010: 58; 57-64.
61.
DOES THE PRESENCE OF ROBOTIC SURGERY AFFECT DEMOGRAPHICS IN PATIENTS CHOOSING TO UNDERGO
RADICAL PROSTATECTOMY? A MULTI-CENTER CONTEMPORARY ANALYSIS.
Philippa J. Cheetham, Daniel J. Lee, Anna Rose-Morris, Simon F. Brewster, Ketan Badani. J
Robotic Surgery 2010.
62.
PROSPECTIVE STUDY OF CURRENT PROSTATE BIOPSY PRACTICES AMONG ONCOLOGICAL UROLOGISTS
Brewster S, Turkeri L, Brausi M, Ravery V, Djavan B. Canadian J
Urol 2010: 17; 5071-5076.
63.
SERIAL ANALYSIS OF RESECTED PROSTATE CANCER SUGGESTS UP-REGULATION OF TYPE 1 IGF RECEPTOR
WITH DISEASE PROGRESSION.
Turney B W, Turner GDH, Brewster SF & Macaulay V.
BJUI 2011: 107; 1488-1499.
64.
TESTICULAR TORSION: A PAINFUL TURN OF EVENTS.
Kirthi, V & Brewster S.
Student BMJ 2011: 19; 26-27.
65.
FOCAL THERAPY IS AN OPTION FOR THE MAJORITY OF LOCALISED PROSTATE CANCERS: HISTOPATHOLOGICAL
STUDY OF CONTEMPORARY UK RADICAL PROSTATECTOMIES
Aslam MA, Turner, G, Brewster SF.
Br J MSU 2011: 4; 166-170.
66.
PROSTATE CANCER: TO SCREEN OR NOT TO SCREEN.
Bailey SJV & Brewster SF.
Arch. Esp. Urol. 2011: 64 (5); 406-418.
67.
EXAMINATION OF THE MALE GENITALIA
Kirthi V., Ellis B. & Brewster S.
Journal of Clinical Examination 2011: 11; 22-31.
68.
THE DIGITAL RECTAL EXAMINATION
Shirley A & Brewster SF.
Journal of Clinical Examination 2011: 11; 1-12.
69.
PSA KINETICS IN THE DIAGNOSIS AND MANAGEMENT OF PROSTATE CANCER
Vickers A & Brewster SF.
British Journal of Medical and Surgical Urology 2012: 5; 162-168
70.
MÜLLERIANOSIS: A RARE CAUSE OF ACUTE RENAL COLIC
Ndokera R, Brewster SF & Dhar S
BMJ Case Reports 2012; doi:10.1136/bcr-2012-006704
71.
Glove at first sight – History of the first surgical rubber glove.
Bhatt JR, Wood IRG, Hobbs CP, Brewster S. Eur Urol 2013; 12(1) Supp 1077
72.
CONTEMPORARY PRACTICE AND TECHNIQUE RELATED OUTCOMES FOR RADICAL PROSTATECTOMY IN THE
UNITED KINGDOM: A REPORT OF NATIONAL OUTCOMES
Laird A, Fowler S, Good S, Stewart G, Srinivasan, Cahill, Brewster SF, McNeill A. on behalf of BAUS Section of Oncology. BJUI
2015: 115: 753-763.
73.
NICE GUIDELINES ON PROSTATE CANCER ACTIVE SURVEILLANCE: IS UK PRACTICE LEADING THE WORLD?
Streeter E & Brewster SF. BJUI 2015: 115; 12-13.
74.
IMPROVING THE DIAGNOSIS AND TREATMENT OF HIGH-RISK LOCALISED OR LOCALLY ADVANCED PROSTATE
CANCER IN THE UK
Payne H, Khoo V, Clarke N, Beresford M, Moore C, AslettP, Bahl A, Bhatt R, Greg Boustead G, Brewster S & Kirby R. Health
Trends 2015: 6; 26-30.
75.
IMPROVING THE SURGICAL TREATMENT OF HIGH-RISK LOCALISED OR LOCALLY ADVANCED PROSTATE
CANCER IN THE UK
Kirby R, Payne H, Khoo V, Clarke N, Beresford M, Moore C, AslettP, Bahl A, Bhatt R, Greg Boustead G &Brewster S. Health
Trends 2015: 6; 29-32.
76.
VARIATION BETWEEN SPECIALIST UROPATHOLGISTS IN REPORTING EXTRAPROSTATIC EXTENSION AFTER
RADICAL PROSTATECTOMY.
Bryant RJ, Schmitt AJ, Roberts ID, Gill S P,Browning L, Brewster SF, Hamdy FC, Verrill CJ. J Clin Pathol 2015; 68: 465–472.
77.
ESTABLISHING NURSE-LED ACTIVE SURVEILLANCE FOR MEN WITH LOCALISED PROSTATE CANCER:
DEVELOPMENT AND FORMATIVE EVALUATION OF A MODEL OF CARE IN THE PROTECT TRIAL.
Julia Wade, Peter N Holding, Susan Bonnington, Leila Rooshenas, J Athene Lane, C Elizabeth Salter, Kate Tilling, Mark J
Speakman, Simon F Brewster, Simon Evans, David E Neal, Freddie C Hamdy, Jenny L Donovan For The Protect Study
Group. BMJ Open 2015;5:e008953.doi:10.1136/bmjopen-2015-008953 22 Sept 2015
78.
UROLOGICAL RECOMMENDATIONS FROM THE NICE GUIDELINE, JUNE 2015: SUSPECTED CANCER:
RECOGNITION AND REFERRAL
Jefferies ER & Brewster SF on behalf of the BAUS Section of Oncology. BJUI 2015 epub ahead of publication; doi:
10.1111/bju13355.
79.
ALTERED EXPRESSION OF MARKERS OF EPITHELIAL-TO-MESENCHYMAL TRANSITION AT
THE EXTRAPROSTATIC EXTENSION COMPONENT OF LOCALLY INVASIVE PROSTATE CANCERS
Bryant RJ, Schmitt AJ, Roberts ID, Gill S P,Browning L, Brewster SF, Hamdy FC, Verrill C. J.. Submitted to Oncotarget 2015.
80.
PROSTATE BIOPSY – WHAT IS THE MOST APPROPRIATE APPROACH? Richard Bryant & Simon Brewster. BJUI Knowledge
2016 https://app.tessello.co.uk/CourseStore/clients/BJUI/71712 Prostatebiopsywhatistheappropr-2016113141647/launch.html doi:
10.18591/BJUIK.0184
81.
HIGH LEVELS OF PATIENT SATISFACTION IN JOINT URO-ONCOLOGY CLINICS TO ASSIST PATIENT CHOICE IN
EARLY PROSTATE CANCER AND MUSCLE-INVASIVE BLADDER CANCER (BMJ.2016.034366) submitted by Dr. Anne
Kiltie
82.
ADVANCES IN UROLOGY 2015-2016. Brewster S, Biers S, Challacombe B, Cresswell J, Sinclair A & Smith D. J Clin Urol 2017;
10: 39-48.